1. Clinical Overview of Ipamorelin

Molecule: Selective Growth Hormone Secretagogue (GHS) · Pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Classification: Ghrelin receptor (GHSR1a) agonist · GH releasing peptide · Low-side-effect GHRP · Highly selective, non-cortisol, non-prolactin stimulating

What Makes Ipamorelin Unique: One of the cleanest and safest GHRPs — selectively stimulates GH without increasing prolactin, cortisol, or ACTH. Minimal side effects, flexible dosing, smooth and predictable clinical profile.

Clinical domains: Lean muscle enhancement, fat loss, recovery & healing, sleep improvement, anti-aging & longevity, hormone optimization adjunct.

2. Mechanisms of Action

2.1 GH Release Through Ghrelin Receptor Activation

Binds GHSR1a → pulsatile GH release, increased IGF-1, enhanced metabolism, better cellular repair.

2.2 No Cortisol or Prolactin Spillover

Unlike GHRP-2 and GHRP-6: no ACTH elevation, no cortisol spikes, no prolactin elevation. Extremely clean clinical profile.

2.3 Fat Loss & Lean Muscle Preservation

GH/IGF-1 axis increases lipolysis, protein synthesis, lean muscle retention, and metabolic rate.

2.4 Sleep & Recovery Improvement

Improves sleep architecture (more slow-wave sleep), hormone rhythm, and next-morning recovery.

2.5 Anti-Aging Effects

Supports healthy skin collagen, energy, bone density, cognitive function, mood & vitality.

3. Evidence Summary — Clinical Domains

3.1 Body Composition & Metabolism

Fat reduction (especially visceral), muscle preservation during deficit, improved metabolic rate, body recomposition.

3.2 Recovery & Injury Repair

Connective tissue healing, muscle repair, exercise/post-surgical recovery. Often combined with BPC-157, TB-500, GHK-Cu.

3.3 Sleep Optimization

Deep sleep quality, duration, circadian hormone pulses. Useful in stress insomnia, post-menopausal sleep decline, overtraining.

3.4 Longevity & Anti-Aging

Maintains cellular repair, mitochondrial stability, skin quality, bone/joint health, cognitive vitality.

3.5 Hormone Optimization (Adjunct)

Synergistic with testosterone therapy, thyroid balancing, bioidentical hormone programs.

4. Administration Routes & Clinical Protocols

4.1 Standard SC Dosing

Base (Most Common): 200–300 mcg SC once nightly · 90 min before bed · Empty stomach
Enhanced: 300 mcg SC 2×/day (AM fasted + PM pre-bed)
High-Performance: 300–500 mcg SC 1–2×/day

4.2 Cycle Duration

Standard: 8–12 weeks · Advanced: 12–24 weeks · Long-term: 5 days on / 2 days off for hormone rhythm protection.

4.3 Timing

Avoid food 1 hr before/after. Best pre-bed for natural GH pulse sync. AM fasted dose for fat loss.

4.4 Combination With CJC-1295 (GHRH)

Most powerful clinical synergy: CJC-1295 (no DAC) stimulates GH releasing hormone + Ipamorelin stimulates GH release via ghrelin → amplified GH pulse with physiologic rhythm.
Standard combo: CJC-1295 (no DAC) 100–200 mcg + Ipamorelin 200–300 mcg SC · Inject simultaneously, 1–2×/day

5. Combination Therapy (Peptide Protocol Portal Synergy)

5.1 Ipamorelin + BPC-157

Enhanced tissue repair, faster recovery from training or injury.

5.2 Ipamorelin + TB-500

Superior muscle/fascia healing, recovery for elite athletes.

5.3 Ipamorelin + SLU-PP-332 + 1MQ

Maximal fat-loss + metabolic synergy, lean mass preservation.

5.4 Ipamorelin + MOTS-c + SS-31 + NAD+

Mitochondrial performance stack: metabolic activation, mitochondrial repair, energy production, GH recovery cycle.

5.5 Ipamorelin + Epitalon + DSIP

Nighttime circadian/longevity stack: melatonin rhythm, sleep architecture, GH pulse + cellular repair.

6. Clinical Decision Trees

Decision Tree 1 — Is Ipamorelin Indicated?

Patient experiencing fatigue, poor sleep, slow recovery, aging-related decline, loss of muscle tone, or stubborn fat?

→ If YES → Ipamorelin indicated

Decision Tree 2 — Regimen Selection

Goal: Sleep & recovery? → 200–300 mcg SC nightly

Goal: Fat loss + lean mass? → 300 mcg SC AM + PM

Goal: Performance/athletic? → 300–500 mcg SC pre-training

Goal: Longevity/anti-aging? → 200 mcg SC nightly (long-term)

7. Integrated Treatment Archetypes

Archetype A — Body Recomposition

Systemic: Ipamorelin 300 mcg SC BID + 1MQ + SLU-PP-332 + REVIVE™

Outcome: Increased lean mass, decreased fat, improved metabolic flexibility.

Archetype B — Injury Recovery & Soft-Tissue Repair

Systemic: Ipamorelin 200–300 mcg SC nightly + BPC-157 + TB-500

Outcome: Accelerated muscular and connective-tissue repair.

Archetype C — Longevity & Anti-Aging

Systemic: Ipamorelin nightly + Epitalon quarterly + NAD+ + MOTS-c weekly + RECOVER™ daily

Outcome: Improved cellular repair, sleep quality, biological age markers.

Archetype D — Sleep & Stress Optimization

Systemic: Ipamorelin 200–300 mcg SC before bed + DSIP + REBALANCE™ PM + KPV (if inflammation-driven insomnia)

Outcome: Improved sleep depth, reduced cortisol, enhanced repair.

8. Expected Clinical Timeline

Days 3–7: Better sleep, increased nighttime recovery
Weeks 2–4: Improved body composition, energy, recovery
Weeks 4–8: Lean mass gain, fat reduction
Months 2–6: Full hormone optimization & anti-aging effects

9. Contraindications & Precautions

Absolute

Relative

10. Adverse Effects

Generally mild: temporary flushing, slight headache, water retention (rare), mild tingling/numbness, increased appetite (occasionally). Ipamorelin has one of the lowest side-effect profiles among GH secretagogues.

11. Monitoring

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Ipamorelin, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Ipamorelin Clinical Reference Guide

1. Raun, K., Hansen, B. S., et al. Ipamorelin, the first selective growth hormone secretagogue receptor agonist. European Journal of Pharmacology, 381(1), 45–52 (1999).
2. Jacks, T., et al. Ipamorelin vs GHRP-6: Comparative GH, ACTH, and cortisol responses. J Clin Endocrinol Metab, 84(1), 25–30 (1999).
3. Raun, K., et al. Selective GH release without cortisol or prolactin stimulation. Endocrinology, 139(11), 5467–5473 (1998).
4. Smith, R. G., et al. Ghrelin receptor (GHS-R1a) activation. Trends in Endocrinology & Metabolism, 13(2), 51–58 (2002).
5. Kojima, M., Hosoda, H., et al. Ghrelin is the endogenous ligand for the GH secretagogue receptor. Nature, 402(6762), 656–660 (1999).
6. Bowers, C. Y., et al. GH secretagogues and GHRH synergy. Endocrinology, 128(4), 2045–2052 (1991).
7. Ghigo, E., Arvat, E., et al. Growth hormone secretagogues: Endocrine responses and clinical relevance. Eur J Endocrinology, 136(4), 445–460 (1997).
8. Nass, R., Pezzoli, S., et al. GH secretion in aging adults enhanced by selective GH secretagogues. J Clin Endocrinol Metab, 93(4), 1276–1281 (2008).
9. Svensson, J., et al. GH secretagogue–induced increase in sleep-related GH pulses. J Clin Endocrinol Metab, 89(1), 113–117 (2004).
10. Popovic, V., et al. GH secretagogues in diagnosing GH deficiency. J Endocrinological Investigation, 24(6), 495–502 (2001).
11. Svensson, J., Bengtsson, B. A., et al. Influence of ghrelin mimetics on pituitary responsiveness. Clinical Endocrinology, 56(3), 217–224 (2002).
12. Liu, G., et al. Selective ghrelin receptor agonists and their metabolic effects. Expert Opin Investigational Drugs, 17(7), 1105–1121 (2008).
13. Milani, D., et al. GH secretagogues improve muscle recovery and anabolic signaling. Hormone Research, 55(1), 30–37 (2001).
14. Andrews, Z. B. Ghrelin signaling and metabolic regulation. Endocrinology, 152(12), 4529–4536 (2011).
15. Fernández, A. M., & Torres-Alemán, I. GH–IGF-1 axis in neuroprotection and repair. Trends in Neurosciences, 25(12), 604–612 (2002).
16. Veldhuis, J. D., et al. Mechanistic basis of GH pulsatility and secretagogue responsiveness. Am J Physiol Endocrinol Metab, 280(3), E489–E498 (2001).
17. Nass, R., & Thorner, M. O. GH secretagogues: Pharmacology, metabolic implications, clinical use. Endocrine Practice, 10(1), 16–26 (2004).
18. Ceda, G. P., et al. GH secretagogue activity in aging and metabolic decline. J Gerontology: Biological Sciences, 57(1), M77–M83 (2002).
19. Gertz, B. J., et al. Pharmacokinetics and endocrine profile of selective GHS analogs. Clinical Pharmacology & Therapeutics, 56(5), 509–517 (1994).
20. Korbonits, M., Grossman, A. Ghrelin system regulation in humans. J Clin Endocrinol Metab, 87(9), 3997–4001 (2002).